Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Identifying the Role of Hypertranscription in Pediatric Tumor Evolution
EF 2021-22
Résumé
Hypertranscription is defined by a global increase of RNA output in a cell. It is an abnormality of a cell's transcriptional machinery best characterized in cancer cell lines and stem cell models. The Shlien lab developed a computational method to measure hypertranscription in thousands of cancers across different adult cancer types, which revealed hypertranscriptions association with aggressive cancer subtypes, and its prognostic utility across adult cancers. Analysis of transcriptomes of individual cells (single cell sequencing) from lung tumors identified groups of hypertranscriptive cells which dominated tumor transcriptional output even when present as a minority cell population. The Shlien labs recent discoveries have elucidated the importance of hypertranscription across adult cancer types, however hypertranscriptions prevalence in pediatric cancers is unknown.The interests of this project lie in understanding the landscape of hypertranscription in pediatric tumours and how cancer cells exhibiting hypertranscription proliferate during tumor growth. To understand hypertranscription in pediatric cancers, genomic data from RNA and DNA sequencing as a part of the SickKids Cancer Sequencing Program (KiCS) will be used. Hypertranscription levels will be measured and compared between cancer types. In single cell sequencing data, hypertranscriptive clones will be identified and tracked over time. Understanding the role of hypertranscriptive clones during tumor evolution will provide fundamental insights into evolution in both adult and pediatric cancers. Results of this project will also nominate candidate tumor types for transcriptional inhibitor therapy and aid in the early identification of aggressive neoplasms.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466973
Name
Wen Timmy T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying the Role of Hypertranscription in Pediatric Tumor Evolution
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cancer Evolution; Hypertranscription; Pediatric Cancer; Relapse; Single Cell Sequencing; Transcription
Abstract
Hypertranscription is defined by a global increase of RNA output in a cell. It is an abnormality of a cell's transcriptional machinery best characterized in cancer cell lines and stem cell models. The Shlien lab developed a computational method to measure hypertranscription in thousands of cancers across different adult cancer types, which revealed hypertranscriptions association with aggressive cancer subtypes, and its prognostic utility across adult cancers. Analysis of transcriptomes of individual cells (single cell sequencing) from lung tumors identified groups of hypertranscriptive cells which dominated tumor transcriptional output even when present as a minority cell population. The Shlien labs recent discoveries have elucidated the importance of hypertranscription across adult cancer types, however hypertranscriptions prevalence in pediatric cancers is unknown.The interests of this project lie in understanding the landscape of hypertranscription in pediatric tumours and how cancer cells exhibiting hypertranscription proliferate during tumor growth. To understand hypertranscription in pediatric cancers, genomic data from RNA and DNA sequencing as a part of the SickKids Cancer Sequencing Program (KiCS) will be used. Hypertranscription levels will be measured and compared between cancer types. In single cell sequencing data, hypertranscriptive clones will be identified and tracked over time. Understanding the role of hypertranscriptive clones during tumor evolution will provide fundamental insights into evolution in both adult and pediatric cancers. Results of this project will also nominate candidate tumor types for transcriptional inhibitor therapy and aid in the early identification of aggressive neoplasms.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wen, Timmy T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~